Brogan, Anita J <br/><br/>
Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.  [electronic resource] 

 -  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research   
 - 657-64 p.  digital 
<br/><br/> Publication Type: Comparative Study; Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4733 
<br/><br/><label>Standard No.: </label>10.1016/j.jval.2011.01.009  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--analogs & derivatives<br/>Adult<br/>Alkynes<br/>Anti-HIV Agents--economics<br/>Antiretroviral Therapy, Highly Active<br/>Benzoxazines--economics<br/>CD4 Lymphocyte Count<br/>Clinical Trials as Topic<br/>Cost Savings<br/>Cost-Benefit Analysis<br/>Cyclopropanes<br/>Deoxycytidine--analogs & derivatives<br/>Dideoxynucleosides--economics<br/>Drug Costs<br/>Emtricitabine<br/>Female<br/>HIV Infections--diagnosis<br/>Health Services Research<br/>Humans<br/>Lamivudine--economics<br/>Male<br/>Markov Chains<br/>Models, Economic<br/>Organophosphonates--economics<br/>Outcome and Process Assessment, Health Care--economics<br/>Quality-Adjusted Life Years<br/>Reverse Transcriptase Inhibitors--economics<br/>Tenofovir<br/>Time Factors<br/>Treatment Outcome<br/>United States--epidemiology<br/>Viral Load<br/>Zidovudine--economics